Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Shandong Analysis and Test Center
WARNING LETTER
•Shandong Analysis and Test Center•January 18, 2017

Shandong Analysis and Test Center – FDA Warning Letter, Jan 18, 2017

Record Details

The FDA issued a Warning Letter to Shandong Analysis and Test Center following an inspection from January 16-18, 2017, identifying significant deviations from current good manufacturing practice (CGMP) for active pharmaceutical ingredients (API), rendering their API adulterated.

Key violations include: 1. **Failure to ensure scientifically sound test procedures:** The facility, a contract testing lab for heparin and heparin-related drugs, failed to routinely establish system suitability for over-sulfated chondroitin sulfate (OSCS) testing using Nuclear Magnetic Resonance (NMR) spectroscopy. A failed system suitability test on December 26, 2014, was not investigated, nor was the reliability of prior tests determined. The company's response acknowledging infrequent system suitability and committing to future routine testing was deemed inadequate for not investigating the validity of past test results. 2. **Failure to prevent unauthorized data access/changes and ensure data integrity:** The quality control unit lacked controls to prevent changes to electronically-stored laboratory data. An analyst admitted to deleting older data to free space. The company's commitment to revise computer permission levels was insufficient as it did not address the deleted data. 3. **Refusal to provide information during inspection:** The facility provided a customer list but withheld sample information and test results for most customers, citing a need for prior consent. This included data for a firm supplying the U.S. heparin market. Such refusal can deem drugs manufactured at

Company
Shandong Analysis and Test Center
Inspection date
January 18, 2017
Product type
Drugs
Office
Center for Drug Evaluation and Research
Person
  • Thomas J. Cosgrove
View Company Profile

ID · a8aded39-4f4d-4e9b-b7f3-7aaeecbf6478

Violation Codes4
FD&C Act 501(a)(2)(B)FD&C Act 801(a)(3)21 U.S.C. 381(a)(3)21 U.S.C. 351(a)(2)(B)

Full citation text and observation details available on the Dashboard.

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Shandong Analysis and Test Center
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.